Pay in 4 interest-free payments of $5.21 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
With dedicated support from a team of passionate clinical pharmacists and proven patient adherence solutions, your patients can be confident to start, continue, and benefit from their GLP-1 therapy
7, 2025: nerandomilast Boehringer Ingelheims oral phosphodiesterase 4B (PDE4B) inhibitor nerandomilast is undergoing a Priority Review for the treatment of idiopathic pulmonary fibrosis (IPF)
Therapeutic Indications and Dosing Protocols Among GLP-1 receptor agonists approved for weight management, liraglutide (SAXENDA) is one of the earliest agents to receive authorization from both the FDA and EMA
GLP1 and cancer: friend or foe
US$ 28.03
US$ 26.32
US$ 24.94
US$ 28.12
